Press Releases
Numinus and MAPS Public Benefit Corporation Announce Collaboration Agreement to Seek Approval of MDMA-Assisted Psychotherapy for PTSD Single-Arm, Open-Label Trial
Numinus and MAPS Public Benefit Corporation announce collaboration agreement to seek approval of MDMA-assisted psychotherapy for PTSD single-arm, open-label trial First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support...
Study: MDMA-Assisted Psychotherapy May Reduce Anxiety for Those Diagnosed with Life-Threatening Illness
Pilot study explored the application of MDMA-assisted psychotherapy in 18 individuals experiencing moderate to severe anxiety following diagnosis with a life-threatening illness The primary outcome, change in State-Trait Anxiety Inventory (STAI) Trait Scores,...
Study: MDMA-Assisted Psychotherapy Will Be Cost-Effective in the Treatment of PTSD
Healthcare cost savings of MDMA-assisted psychotherapy for PTSD estimated to be greater than $103.2 million with a return of 5,553 Quality of Life Years per 1,000 patients Santa Cruz, CA, October 14, 2020 – A peer-reviewed study published today in the research journal...
MAPS Public Benefit Corporation Welcomes Jason Pyle, CEO at Empower Health Equity, to the Board of Directors and Names Amy Emerson as CEO
MAPS Public Benefit Corporation (MAPS PBC) welcomes Jason Pyle, an experienced CEO and executive leader, to their Board of Directors. A wholly-owned subsidiary of the Multidisciplinary Association of Psychedelic Studies (MAPS), MAPS PBC catalyzes healing and...
MDMA-Assisted Psychotherapy May Have Lasting Benefits for PTSD, Results Published in Psychopharmacology
MEDIA CONTACT:Brad Burge, Director of Strategic Communications, [email protected] GENERAL QUESTIONS:[email protected] Today, the non-profit Multidisciplinary Association for Psychedelic Studies (MAPS) announced the publication of the long-term follow-up results of six...
Psychopharmacology Publishes Combined Analysis of Phase 2 Clinical Trials of MDMA-Assisted Psychotherapy for PTSD
Today, the overall results of six Phase 2 clinical trials of MDMA-assisted psychotherapy for the treatment of posttraumatic stress disorder (PTSD) were published in the peer-reviewed journal Psychopharmacology. The paper is the most comprehensive analysis yet published of research into the efficacy and safety of MDMA-assisted psychotherapy for PTSD.
Participant Screening Begins in Phase 3 Clinical Trials of MDMA-Assisted Psychotherapy for PTSD
Five sites in California, Colorado, Louisiana, and South Carolina now open for enrollment inquiries, with more opening soon. All-new video—Breakthrough for Psychedelic Medicine—explains how individuals can support non-profit research for PTSD and other mental health conditions